Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
GlobalData’s reports offer expert analysis, insights and opinions to companies in the world’s largest industries. Explore unique market-leading data today and benefit from access to actionable insight within the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) market. Reports cover market growth forecasts, trends and research, and more.
Browse our full list of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) market reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Product Insights
NewProduct Insights NewMucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
$2,500 | March 2024 Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trial Report Overview A total of 97 Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials were conducted as of March 2024. The Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial report provides a comprehensive understanding of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the...
-
Product Insights
Product Insights Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Drugs In Development, 2023 Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Drugs In Development, 2023’, provides an overview of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.